Conclusion
In current times, the use of immune checkpoint inhibitors for the
treatment of various cancers has increased rapidly. Thus, it has become
essential to understand various irAEs associated with their use and
monitoring of these irAEs in patients undergoing immunotherapy. There is
an extensive range of cutaneous adverse reactions observed with
PD-1/PD-L1 immune checkpoint inhibitors and they account for the most
significant share of immune-related adverse events that range from mild
to life-threatening complications such as stevens-johnson syndrome/
toxic epidermal necrolysis (TEN). The time of occurrence of these
reactions usually varies from days to several months. The most common
cutaneous adverse reactions observed are lichenoid reactions,
granulomatous skin reactions, pruritus, pigmentary disorders such as
vitiligo. The blocking of the PD-1/PD-L1 signaling pathway is involved
in the pathophysiology of numerous autoimmune skin diseases like bullous
pemphigoid, psoriasis, vasculitis, and dermatomyositis. The management
of skin toxicity from anti-PD-1/PD-L1 treatment involves topical and
systemic corticosteroids, immunosuppressive drugs, antihistamines,
UVB-NB therapy. Furthermore, adequate management of the cutaneous
adverse events and recognition in early stages could lead to the
prevention of worsening of the lesions, reduction in morbidity and thus,
enhances the chances of continuing PD-1/PD-L1 therapies without limiting
the treatment.
Acknowledgment: Authors like to acknowledge support from the
University Institute of Pharmaceutical Sciences, Panjab University,
Chandigarh.
Conflicts of interest: The authors declare that they
have no competing interests.
Funding: This research did not receive any specific grant from
funding agencies in the public, commercial, or not-for-profit
sectors.